Method for preparing sterile injectable agent containing teriparatide or salt thereof
WO2021002371A1
Glycosylated protein assay reagent containing protease stabilizer increasing redox potential of ferrocyanide, method for assaying glycosylated protein, method for preserving glycosylated protein assay reagent, and method for stabilizing glycosylated protein assay reagent
US2020101139A1
Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent
WO2020080249A1
Enzymatic measurement method and reagent for enzymatic measurement
TW202023537A
Medication for alleviating symptoms of peripheral neuropathy caused by anticancer drug and/or suppressing onset of peripheral neuropathy
WO2020071279A1
Method for assisting prediction of shunt trouble and kit therefor
WO2020084853A1
Drug for treating and/or improving septicemia associated with coagulation abnormality
WO2020090174A1
Method for preventing or treating osteoporosis characterized by administering teriparatide or salt thereof twice a week
WO2019131582A1
Nitrogen-containing six-membered ring compound
CA3075977A1
Teriparatide-containing liquid pharmaceutical composition having excellent stability
US2020289622A1
Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
WO2019220654A1
Preparation having reduced n-formylpiperidine content and/or rarely undergoing collapse or shrinkage of lyophilized cake thereof
WO2018021098A1
Method for measuring glycated albumin
WO2017221795A1
MEASUREMENT OF Lp-PLA2 ACTIVITY
EP3449825A1
Estimation device
WO2017006908A1
Agent for preventing onset of idiopathic osteonecrosis of femoral head and/or suppressing progress of same
US2017306389A1
Measuring method and composition using kinase
AU2014218380A1
PTH-containing therapeutic/prophylactic agent for osteoporosis, characterized in that PTH is administered once a week at unit dose of 100 to 200 units
EP2987867A4
Method for measuring activity of human pancreatic lipase
